upfront 治疗：持续治疗的案例。
Upfront therapy: the case for continuous treatment.
机构信息
Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; University of Melbourne, Parkville, Victoria, Australia; and The Royal Melbourne Hospital, Parkville, Victoria, Australia.
出版信息
Hematology Am Soc Hematol Educ Program. 2021 Dec 10;2021(1):55-58. doi: 10.1182/hematology.2021000232.
Both BTKi and BCL2i are regarded as standards of care for frontline treatment of CLL. In this paper, I present the arguments for favoring BTKi as initial therapy. Venetoclax-based regimens have the advantage of being fixed in duration, but patients with select high-risk features may experience inferior PFS relative to those without high-risk features.
BTKi 和 BCL2i 均被认为是 CLL 一线治疗的标准治疗方法。在本文中，我提出了赞成 BTKi 作为初始治疗的理由。基于 Venetoclax 的方案具有治疗时间固定的优势，但具有某些高危特征的患者与无高危特征的患者相比，PFS 可能较差。
相似文献
Hematology Am Soc Hematol Educ Program. 2021-12-10
Cancer. 2024-10-1
Hematology Am Soc Hematol Educ Program. 2021-12-10
Hematology Am Soc Hematol Educ Program. 2020-12-4
Hematology Am Soc Hematol Educ Program. 2021-12-10
引用本文的文献
本文引用的文献
N Engl J Med. 2020-7-30
Curr Hematol Malig Rep. 2020-6
Zotero 插件